我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

利伐沙班对apoE-/-小鼠颈动脉粥样硬化斑块内炎症因子表达的影响

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2016年第5期
页码:
531-533
栏目:
基础研究
出版日期:
2016-04-25

文章信息/Info

Title:
Rivaroxaban restrains IL-6, TNF-α and MMP9 expressions in carotid atherosclerotic plaques in apoE-/- mice
作者:
霍倩倩; 孔 营
（山东省济宁第一人民医院心内科，山东 济宁 272000）
Author(s):
HUO Qian-qian;  KONG Ying
(Department of Cardiology, Jining First People's Hospital of, Jining 272000, Shandong, China)
关键词:
利伐沙班; 动脉粥样硬化; 炎症因子
Keywords:
rivaroxaban;  carotid atherosclerotic plaques;  inflammatory factor
分类号:
R543.5
DOI:
-
文献标识码:
A
摘要:
目的 探讨选择性Xa因子抑制剂利伐沙班（RVXB）对apoE-/-小鼠颈动脉粥样硬化斑块内炎症因子表达的影响。方法 20只apoE-/-小鼠随机分为对照组和利伐沙班组（每组10只）。所有小鼠通过高脂喂养及颈动脉套管方法建立颈动脉粥样硬化斑块模型。8周后，对照组小鼠接受生理盐水灌胃，而利伐沙班组小鼠接受每天5 mg/kg剂量利伐沙班灌胃；给药4周后，测量小鼠体质量并处死小鼠。采用Western blot方法检测斑块内IL-6，TNF-α和MMP9蛋白表达水平。结果 与对照组相比，利伐沙班组小鼠的体质量及血脂水平无显著改变；斑块内IL-6，TNF-α和MMP9蛋白表达水平显著降低（均P<0.05）。结论 利伐沙班能够抑制动脉粥样硬化斑块内炎症因子的表达。
Abstract:
AIM To investigate how rivaroxaban, an FXa alternative inhibitor, influences the inflammatory factor expression in carotid atherosclerotic plaques in apoE-/- mouse. METHODSWe divided 20 apoE-/- mice randomly into control group and rivaroxaban group (n=10 each). The models of carotid atherosclerotic plaques were established with high-fat food and carotid artery casing in all mice. After 8 weeks, mice in the control group were given physiological saline by intragastric administration and mice in the rivaroxaban group were given rivaroxaban 5 mg/kg by intragastric administration. After 4 weeks of continuous administration, mice were euthanized after body weight was measured. The expression levels of IL-6 (interleukin-6), TNF-α (tumor necrosis factor-alpha) and MMP9 (matrix metalloproteinase 9) in plaques were measured by Western blot. RESULTSCompared with those in the control group, the weight and lipid levels in the rivaroxaban group were not obviously changed, but the expression levels of IL-6, TNF-α and MMP9 were reduced significantly (P<0.05). CONCLUSIONRivaroxaban inhibits inflammatory factor expression in atherosclerotic plaques.

参考文献/References

[1]Davies MJ.Pathophysiology of acute coronary syndromes[J].Heart,2000,83(3):361-366.
[2]Hansson GK.Inflammation,atherosclerosis,and coronary artery disease[J].N Engl J Med,2005,352(16):1685-1695.
[3]Mega JL,Braunwald E,Mohanavelu S,et al.Rivaroxaban versus placebo in patients with acute coronary syndromes(ATLAS ACS-TIM I 46):a randomised, double-blind, phase II trial[J].The Lancet,2009,374(9683):29-38.
[4]Bea F1,Kreuzer J,Preusch M,et al.Melagatran reduces advanced atherosclerotic lesion size and may promote plaque stability in apolipoprotein E-deficient mice[J].Arterioscler Thromb Vasc Biol,2006,26(12):2787-2792.
[5]Insull W Jr.The pathology of atherosclerosis:plaque development and plaque responses to medical treatment[J].Am J Med,2009,122(1 Suppl):S3-S14.
[6]Ross R.Atherosclerosis is an inflammatory disease[J].Am Heart J,1999,138(5 Pt 2):S419-S420.
[7]Li JJ,Meng X,Si HP,et al.Hepcidin destabilizes atherosclerotic plaque via overactivating macrophages after erythrophagocytosis[J].Arterioscler Thromb Vasc Biol,2012,32(5):1158-66.
[8]Davie EW,Fujikawa K,Kisiel W.The coagulation cascade:initiation,maintenance,and regulation[J].Biochemistry,1991, 30(43):10363-10370.
[9]Daubie V,Cauwenberghs S,Senden NH,et al.Factor Xa and thrombin evoke additive calcium and proinflammatory responses in endothelial cells subjected to coagulation[J].Biochim Biophys Acta,2006, 1763(8):860-869.
[10]Wakefield TW,Strieter RM,Wilke CA,et al.Venous thrombosis-associated inflammation and attenuation with neutralizing antibodies to cytokines and adhesion molecules[J].Arterioscler Thromb Vasc Biol,1995,15(2):258-268.
[11]D?rffler-Melly J,Schwarte LA,Ince C,et al.Mouse models of focal arterial and venous thrombosis[J].Basic Res Cardiol,2000,95(6):503-509.
[12]Perzborn E,Strassburger J,Wilmen A,et al.In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor[J].J Thromb Haemost,2005,3(3):514-521.
[13]EINSTEIN Investigators,Bauersachs R,Berkowitz SD,et al.Oral rivaroxaban for symptomatic venous thromboembolism[J].N Engl J Med,2010,363(26):2499-2510.
[14]Gensch C,Hoppe U,B?hm M,et al.Late-breaking clinical trials presented at the American Heart Association Congress in Chicago 2010[J].Clin Res Cardiol,2011,100(1):1-9.

备注/Memo

备注/Memo:
收稿日期：2015-01-19.
通讯作者：孔营,主治医师，主要从事动脉粥样斑块发生机制研究 Email：EMAIL:ky46@163.com
作者简介：霍倩倩，主治医师，硕士 Email：hqq1984@163.com
更新日期/Last Update: 2016-04-13